Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate a Significantly Improved… Aug 31, 2021
Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in its Long-Acting Next… Aug 26, 2021
Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired… Aug 24, 2021
Mindset Pharma Announces Publication of Three PCT Patent Applications for Its Next Generation Psychedelic Drug… Aug 16, 2021
Mindset Pharma Announces Preclinical Results Demonstrating Superior Efficacy, Safety and Shorter Duration of Action… Aug 10, 2021
Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board Jul 20, 2021
Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program Jun 14, 2021
Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds Apr 29, 2021
